Pharmacokinetics of3H-phenylephrine in man

Summary

7-3H-phenylephrine was given to 15 volunteers by a short-infusionn=4) or p.o. (10 volunteers, 1 patient with porto-caval anastomosis). Analysis of serum for free3H-phenylephrine and fractionation of urinary radioactivity was performed by ion-exchange and thin-layer chromatography. As almost the same3H-activity was excreted in urine after i.v. and p.o. administration, 86% and 80% of the dose respectively, complete enteral absorption can be assumed. A considerable difference was seen in the fraction of free phenylephrine, i.v. 16% of the dose versus p.o. 2.6%, which suggested reduced bioavailability. This was confirmed by comparison of the areas under the serum curve, which showed a bioavailability factor of 0.38. The result for the patient with porto-caval anastomosis was comparable to that in the normal volunteers. The biological half-life of 2 to 3h was comparable to that of structurally related amines, as were the total clearance of 2 1/h, and the volume of distribution of 340l. Metabolism to phenolic conjugates mainly after oral ingestion, and tom-hydroxymandelic acid after i.v. injection, again demonstrated thatm-hydroxylated amines are predominantly conjugated during the “first-pass” metabolism.

This is a preview of subscription content, access via your institution.

References

  1. Ahlquist RP, Levy B (1959) Adrenergic receptive mechanism of canine ileum. J Pharmacol Exp Ther 127: 146–149

    Google Scholar 

  2. Barger G, Dale HH (1910) Chemical structure and sympathomimetic action of amines. J Physiol (Lond) 41: 19–59

    Google Scholar 

  3. Besarab A, Silva P, Landsberg L, Epstein F (1977) Effect of catecholamines on tubular function in the isolated perfused rat. Am J Physiol 233: F39-F45

    Google Scholar 

  4. Borromeo-McGrail V, Bordiuk JM, Keitel H (1973) Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. Pediatrics 51: 1032–1036

    Google Scholar 

  5. Bruce RB, Pitts JE (1968) The determination and excretion of phenylephrine in urine. Biochem Pharmacol 17: 335–337

    Google Scholar 

  6. Dost FH (1968) Grundlagen der Pharmakokinetik. Thieme Verlag, Stuttgart

    Google Scholar 

  7. Elis J, Laurence DR, Mattie H, Prichard BNC (1967) Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J 2: 75–78

    Google Scholar 

  8. Fraunfelder FT, Scafidi AF (1978) Possible adverse effects from topical ocular 10% phenylephrine. Am J Ophthalmol 85: 447–453

    Google Scholar 

  9. Govier WC (1967) A positive inotropic effect of phenylephrine mediated through alpha adrenergic receptors. Life Sci 6: 1361–1365

    Google Scholar 

  10. Hengstmann JH (1976) Metabolic pattern and pharmacokinetic properties of phenolic sympathomimetic amines. Arzneim-Forsch (Drug Res) 26: 1254–1255

    Google Scholar 

  11. Hengstmann JH, Aulepp H (1978) Pharmakokinetik und Metabolismus von3H-Synephrin. Arzneim-Forsch (Drug Res) 28: 2326–2331

    Google Scholar 

  12. Hengstmann JH, Goronzy J (1980) Enterale Resorption und Bioverfügbarkeit von Norfenefrin. Arzneim-Forsch. (Drug Res) 30: 2164–2167

    Google Scholar 

  13. Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJ (1974) The physiological disposition ofp-octopamine in man. Naunyn-Schmiedebergs Arch Pharmacol 283: 93–106

    Google Scholar 

  14. Hengstmann JH, Konen W, Konen C, Eichelbaum M, Dengler HJ (1975a) Bioavailability ofm-octopamine in man related to its metabolism. Eur J Clin Pharmacol 8: 33–39

    Google Scholar 

  15. Hengstmann JH, Weyand U, Dengler HJ (1975b) The physiological disposition of etilefrine in man. Eur J Clin Pharmacol 9: 179–187

    Google Scholar 

  16. Horvath SM, Knapp DW (1954) Hemodynamic effects of neosynephrine. Am J Physiol 178: 387–391

    Google Scholar 

  17. Innes IR, Nickerson M (1975) Norepinephrine, epinephrine and the sympathomimetic amines. In: Gilman A, Goodman LS (eds) The pharmacological basis of therapeutics. 5th ed. Macmillan, New York, pp 477–513

    Google Scholar 

  18. Kuschinsky G, Oberdisse K (1931) Die Kreislaufwirkungen des Meta-Sympatols. Arch Exper Pathol Pharmakol 162: 46–55

    Google Scholar 

  19. Leong LSK, Benfey BG (1968) Actions of phenylephrine on contractility and rate of rabbit atria. Pharmacologist 10: 206

    Google Scholar 

  20. Martinez TT, McNeill JH (1977) Cyclic AMP and the positive inotropic effect of norepinephrine and phenylephrine. Can J Physiol Pharmacol 279–287

  21. Quebbemann AJ, Rennick BR (1968) Catechol transport by the renale tubule in the chicken. Am J Physiol 214: 1201–1204

    Google Scholar 

  22. Reinhardt D, Wagner J (1974) Beat-adrenolytic, antiarrhythmic and local anaesthetic effects of phenylephrine. Naunyn-Schmiedebergs Arch Pharmacol 284: 245–261

    Google Scholar 

  23. Riegelman S, Loo JC, Rowland M (1968) Concept of a volume of distribution and possible errors in evaluation of this parameter. J Pharm Sci 57: 128–133

    Google Scholar 

  24. Trendelenburg U, Muskus A, Flemming WW, Gomez Alonsa de la Sierra B (1962) Modification by reserpine of the action of sympathomimetic amines in spinal cats: a classification of sympathomimetic amines. J Pharmacol Exp Ther 138: 170–180

    Google Scholar 

Download references

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hengstmann, J.H., Goronzy, J. Pharmacokinetics of3H-phenylephrine in man. Eur J Clin Pharmacol 21, 335–341 (1982). https://doi.org/10.1007/BF00637623

Download citation

Key words

  • phenylephrine
  • pharmacokinetics
  • bioavailability
  • first-pass metabolism
  • phenolic conjugates
  • m-hydroxymandelic acid
  • intravenous
  • oral